STOCK TITAN

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in central nervous system (CNS) disorders therapeutics, has announced its participation in the 43rd Annual J.P.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in central nervous system (CNS) disorders therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and Chairman, Sharon Mates, Ph.D., will deliver a presentation on Monday, January 13, 2025, at 11:15 a.m. PT in San Francisco.

Interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section of the company's website at www.intracellulartherapies.com. Attendees are advised to log in 5-10 minutes before the presentation to complete registration and software installation if necessary.

Loading...
Loading translation...
Argus Session date unavailable
-2.32% session move Open Argus
Details

News Market Reaction – ITCI

The recorded move for ITCI in the trading session of this news was -2.32%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com.  Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com 
646-930-4406


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is ITCI presenting at the 2025 J.P. Morgan Healthcare Conference?

Intra-Cellular Therapies (ITCI) is scheduled to present on Monday, January 13, 2025, at 11:15 a.m. PT in San Francisco.

How can investors watch ITCI's J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through both live and archived webcasts available in the 'Events & Presentations' section of www.intracellulartherapies.com.

What is the focus area of ITCI's therapeutic development?

ITCI focuses on the development and commercialization of therapeutics for central nervous system (CNS) disorders.

Who will be presenting for ITCI at the 2025 J.P. Morgan Healthcare Conference?

Sharon Mates, Ph.D., who serves as Chief Executive Officer and Chairman of Intra-Cellular Therapies, will be presenting at the conference.

Keep reading